WuXi AppTec is to expand its facilities in San Diego, by establishing a centre of excellence in screening, discovery biology, pharmacology and small molecule proc

API and finished dosage form manufacturer Cambrex is investing $1 million at its site in High Point, North Carolina, in response to a growing number of new projects.

France’s Roquette has completed the acquisition of a majority stake in Crest Cellulose, from Pravesha Industries, a major pharmaceutical packaging company in India, and formed a joint ventu

Lonza Pharma & Biotech has concluded an agreement, under which GE Healthcare will deliver an off-the-shelf biologics facility to it in Guangzhou, China, by 2020. The company said that the new facility would give it “a strategic base in China to respond to growing demand for high-quality CDMO services in the country”.

DSM Sinochem Pharmaceuticals has new identity under private equity owner

Boehringer Ingelheim (BI) has started the construction of a new production facility for innovative drugs. The new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches. 

The research-driven pharmaceutical company is investing €85 million (US$99.3 million) in Ingelheim, focusing on modern and flexible production.

Pharmaceutical giant Pfizer is reorganising its company into three businesses to help the company “achieve its growth potential”. 

A science-based Innovative Medicines business will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables. These units possess significant therapeutic area expertise in the medical, commercial and patient experience domains and will provide a strong commercialisation platform for these medicines.